Status:
COMPLETED
Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment
Lead Sponsor:
Centre Henri Becquerel
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of this study is to describe the early dynamics of 18-FDG uptake in non smal cell lung cancer during first line treatment with pembrolizumab, and to evaluate whether or not they differ accordi...
Detailed Description
Immunotherapy with anti-PD1 antibody, such as Pembrolizumab, is widely used in the treatment of stage III/IV non small cell lung cancer. In order to refine treatments and patients' prognosis, early as...
Eligibility Criteria
Inclusion
- Non operable non small cell lung cancer
- Indication of treatment by Pembrolizumab
- PD-L1 status superior to 50 %
- Age more than 18 years
- At least one measurable target
- Written inform consent
Exclusion
- no treatment by pembrolizumab
- immunosuppressive treatment
- uncontrolled diabete
- Pregnancy or breast-feeding
- curatorship or guardianship
- not possibility to follow-up the procedures of the study due to geographic, social or psychic reasons
Key Trial Info
Start Date :
June 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 3 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03832348
Start Date
June 17 2019
End Date
July 3 2024
Last Update
January 2 2026
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Henri Becquerel
Rouen, France, 76000
2
CHU
Rouen, France, 76000